GO
Loading...

Enter multiple symbols separated by commas

Life Sciences

More

  • Feb 10- Valeant Pharmaceuticals International Inc appears poised to scoop up bankrupt cancer vaccine maker Dendreon Corp after another potential buyer dropped from the bidding process, three sources close to the sale told Reuters. Valeant, of Laval, Quebec, has agreed to pay $400 million for the assets of Seattle- based Dendreon, best known for its Provenge...

  • Valeant, of Laval, Quebec, has agreed to pay $400 million for the assets of Seattle- based Dendreon, best known for its Provenge cancer treatment.

  • LONDON, Feb 1- As West Africa's devastating Ebola outbreak begins to dwindle, scientists are looking beyond the endgame at the kind of next-generation vaccines needed for a vital stockpile to hit another epidemic hard and fast. Determined not to lose scientific momentum that could make the world's first effective Ebola interventions a reality, researchers...

  • Jan 30- Shares of Spark Therapeutics Inc more than doubled in their debut, valuing the gene-therapy company at nearly $1.5 billion and underscoring investor's interest in the field that recently produced a million-dollar drug. The company's shares opened at $45.10 in their debut on Friday, nearly double their IPO price of $23, and soared to a high of $50 with...

  • Robert Califf, a top cardiologist and researcher, to oversee its drug, medical device and tobacco policy in what experts said is a coup for the FDA. "This is a great catch for the FDA," said Dr. Califf has run countless clinical studies, published more than 1,000 papers, served as an FDA adviser and has twice been interviewed as a potential FDA commissioner.

  • Jan 26- The U.S. Food and Drug Administration approved Rockwell Medical Inc's drug for treating iron loss in chronic kidney disease patients on dialysis, sending the company's shares up about 15 percent in premarket trading. Samimy said she expected Triferic to hit peak sales of $200 million- $250 million in the United States. Rockwell estimates the market for...

  • LONDON, Jan 23- The first batch of GlaxoSmithKline's experimental Ebola vaccine has been dispatched to West Africa and is expected to arrive in Liberia later on Friday, the British drugmaker said. The World Health Organization said on Thursday the Ebola outbreak in West Africa, the worst in history, appears to be waning but cautioned against complacency.

  • LONDON, Jan 23- The first batch of GlaxoSmithKline's experimental Ebola vaccine has been shipped to West Africa and is expected to arrive in Liberia later on Friday, the British drugmaker said. The vaccine, co-developed by the National Institutes of Health in the United States and Okairos, a biotechnology firm acquired by GSK in 2013, is currently being tested...

  • Jan 21- The U.S. Food and Drug Administration approved Novartis AG's injectable drug, Cosentyx, to treat adults with a moderate to severe skin disease called plaque psoriasis. Eli Lilly and Co will begin marketing its IL-17 inhibitor ixekizumab in the first half of 2015, while Amgen Inc and AstraZeneca Plc's brodalumab reported positive results from a...

  • The cost of halting a pandemic? $344 billion: Study Saturday, 17 Jan 2015 | 12:15 PM ET
    A custodial worker wears a mask and eye protection to guard against the Ebola virus as he prepares to clean Ruth Cherry Intermediate School in Dallas.

    How much would it cost world governments to insulate their economies from global pandemics. Would you believe nearly $344 billion?

  • LONDON, Jan 16- Johnson& Johnson said on Friday that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros from Europe's Innovative Medicines Initiative to speed development. The new initiative will see J&J join with institutions including the London School of Hygiene& Tropical Medicine, the University of...

  • SHANGHAI, Jan 15- China has approved a new polio vaccine, the first of its kind to be produced in the country, a month after local authorities gave the green light for a home-grown Ebola vaccine amid Beijing's push to become a world leader in producing innovative drugs. "This new vaccine is a critically important weapon in the fight against polio as the world nears...

  • Jan 11- Canada's Tekmira Pharmaceuticals Corp agreed to buy Pennsylvania- based OnCore Biopharma Inc to focus on developing hepatitis B virus treatment by combining multiple therapeutic methods. The implied market value of the merged company is about $750 million, based on Tekmira stock's closing price of $15.70 on the Nasdaq on Jan. 9, the companies said in a...

  • *Initial Phase I clinical study starts in Britain. *First tests in Britain, more planned in U.S. and Africa. LONDON, Jan 6- Johnson& Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic, making it the third such shot to enter human testing.

  • *Initial Phase I clinical study starts at Oxford University. *Further tests planned for United States and Africa. LONDON, Jan 6- Johnson& Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic, making it the third such shot to enter human testing.

  • Record iPhone 6 sales would have been even better Monday, 22 Sep 2014 | 11:04 AM ET
    iPhone 6 Plus

    In Monday's The Good, The Bad, and The Ugly: iPhone 6 sales top record; a poll shows attitudes towards corporations; and a German firm shops in U.S.

  • German firm buys American, but not for taxes: CEOs Monday, 22 Sep 2014 | 8:09 AM ET
    The Merck KGaA logo sits outside the company's headquarters in Darmstadt, Germany.

    Merck agrees to acquire Sigma-Aldrich for $17 billion in cash to boost its life science business.

  • Medical marijuana research hits wall of US law Sunday, 10 Aug 2014 | 7:54 AM ET
    A man purchases medical marijuana, the first legal sale, at Capital City Care in Washington, DC. The District of Columbia city council is to vote on decriminalizing pot.

    U.S. scientists face legal obstacles and frustrations in trying to study the medical uses of marijuana, the New York Times reports.

  • AstraZeneca Chair: Shareholders, 'vote me away' Monday, 19 May 2014 | 11:14 AM ET

    As AstraZeneca's shares slid following its rejection of Pfizer's new bid, the company's chairman said he was "reasonably confident" it was the right decision.

  • Euro strength still hurting business: DSM CFO Friday, 9 May 2014 | 3:47 AM ET

    The escalating euro continues to harm business, the chief financial officer of Royal DSM told CNBC, a day after the single currency took a beating.